Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

BMEA

Biomea Fusion (BMEA)

Biomea Fusion Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BMEA
DateTimeSourceHeadlineSymbolCompany
14/01/202501:00GlobeNewswire Inc.Biomea Fusion to Become a Diabetes & Obesity Medicines CompanyNASDAQ:BMEABiomea Fusion Inc
08/01/202501:00GlobeNewswire Inc.Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination StudyNASDAQ:BMEABiomea Fusion Inc
07/01/202508:57Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BMEABiomea Fusion Inc
06/01/202523:00GlobeNewswire Inc.Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BMEABiomea Fusion Inc
21/12/202407:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
18/12/202400:10GlobeNewswire Inc.Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesNASDAQ:BMEABiomea Fusion Inc
17/12/202410:15GlobeNewswire Inc.Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)NASDAQ:BMEABiomea Fusion Inc
13/12/202409:02GlobeNewswire Inc.Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)NASDAQ:BMEABiomea Fusion Inc
10/12/202408:01GlobeNewswire Inc.Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaNASDAQ:BMEABiomea Fusion Inc
07/12/202400:00GlobeNewswire Inc.Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute LeukemiaNASDAQ:BMEABiomea Fusion Inc
03/12/202408:05GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
19/11/202400:00GlobeNewswire Inc.Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)NASDAQ:BMEABiomea Fusion Inc
02/11/202407:05GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
31/10/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
31/10/202407:00GlobeNewswire Inc.Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist CandidateNASDAQ:BMEABiomea Fusion Inc
30/10/202408:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMEABiomea Fusion Inc
30/10/202408:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
30/10/202407:46GlobeNewswire Inc.Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
22/10/202400:00GlobeNewswire Inc.Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219NASDAQ:BMEABiomea Fusion Inc
16/10/202407:05GlobeNewswire Inc.Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RNASDAQ:BMEABiomea Fusion Inc
08/10/202400:00GlobeNewswire Inc.Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)NASDAQ:BMEABiomea Fusion Inc
02/10/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
01/10/202423:00GlobeNewswire Inc.Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes ExpertsNASDAQ:BMEABiomea Fusion Inc
28/09/202406:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
27/09/202404:00GlobeNewswire Inc.FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes TrialsNASDAQ:BMEABiomea Fusion Inc
02/08/202406:05GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
01/08/202406:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMEABiomea Fusion Inc
01/08/202406:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
01/08/202406:05GlobeNewswire Inc.Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
14/06/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
 Showing the most relevant articles for your search:NASDAQ:BMEA

Your Recent History

Delayed Upgrade Clock